Controlled-Release Microparticles for Local Treg Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive drug therapies for transplantation rejection and immunological disorders cause long-term side effects and systemic toxicity, necessitating a method to target regulatory T cells specifically to affected tissues without systemic immunosuppression.
Innovation Solution
Custom-designed microparticles with controlled release profiles deliver T cell inducing factors to target tissues, allowing differential temporal and spatial activation of regulatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive drugs are administered systemically to prevent transplantation rejection, then rejection of allografts is decreased, but toxicity and side effects increase
Solution Approach 1:
The patent applies local quality by delivering immunosuppressive agents specifically to the target tissue (transplanted organ) rather than systemically. This is achieved through targeted delivery systems that concentrate the therapeutic effect at the graft site while minimizing exposure of healthy tissues to the immunosuppressive drugs, thereby reducing toxicity and side effects while maintaining prevention of transplantation rejection
Solution Approach 2:
The patent uses targeted delivery systems (such as antibody-drug conjugates or ligand-receptor mediated delivery) as intermediaries to transport immunosuppressive agents from the bloodstream to the target tissue. These intermediaries enable selective accumulation of the drug at the graft site through specific binding interactions, reducing systemic exposure while ensuring adequate drug delivery to prevent rejection
2Duration of action of stationary object
If immunosuppressive drugs are administered long-term to avoid acute and chronic rejection, then graft survival is improved, but vulnerability to infections and malignancies increases
Solution Approach 1:
The patent implements local quality by maintaining high concentrations of immunosuppressive agents specifically at the graft site over the long term, while keeping systemic levels low. This spatial differentiation allows sustained graft protection without the prolonged systemic immunosuppression that leads to increased vulnerability to infections and malignancies
Solution Approach 2:
The patent ensures continuous delivery of immunosuppressive agents to the target tissue through sustained-release formulations or continuous targeted delivery mechanisms. This maintains adequate drug levels at the graft site throughout the long-term period necessary for preventing both acute and chronic rejection, while minimizing systemic exposure through localized action
Data Source
AI summary
The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-β, and/or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy.